Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
SEPN is expected to report earnings to rise 168.97% to -77 cents per share on November 25
Q3'26
Est.
$-0.78
Q2'26
Beat
by $0.45
Q1'26
Beat
by $0.55
Q4'25
Beat
by $0.48
Q3'25
Beat
by $0.83
The last earnings report on August 10 showed earnings per share of -28 cents, beating the estimate of -74 cents. With 185.57K shares outstanding, the current market capitalization sits at 1.85B.